Adar1 Capital Management, LLC Cerevel Therapeutics Holdings, Inc. Transaction History
Adar1 Capital Management, LLC
- $441 Billion
- Q1 2024
A detailed history of Adar1 Capital Management, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 24,259 shares of CERE stock, worth $1.04 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
24,259
Previous 110,700
78.09%
Holding current value
$1.04 Million
Previous $4.69 Billion
78.15%
% of portfolio
0.23%
Previous 1.68%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
229Shares Held
150MCall Options Held
969KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.82 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$463 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$324 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$320 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$234 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.68B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...